A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

The existing work examined the potential of utilizing ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells As well as in cells missing purposeful p53 possibly alone or in combination with tamoxifen, even though the effectiveness of ABBV